ETON vs. NAMS, APGE, BLTE, TVTX, IRON, WVE, IOVA, EVO, PRAX, and AMPH
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Belite Bio (BLTE), Travere Therapeutics (TVTX), Disc Medicine (IRON), Wave Life Sciences (WVE), Iovance Biotherapeutics (IOVA), Evotec (EVO), Praxis Precision Medicines (PRAX), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry.
Eton Pharmaceuticals vs.
NewAmsterdam Pharma (NASDAQ:NAMS) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability.
Eton Pharmaceuticals received 71 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 65.07% of users gave Eton Pharmaceuticals an outperform vote.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
NewAmsterdam Pharma has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
NewAmsterdam Pharma has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -15.81%. NewAmsterdam Pharma's return on equity of 0.00% beat Eton Pharmaceuticals' return on equity.
In the previous week, NewAmsterdam Pharma had 3 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 1 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.74 beat NewAmsterdam Pharma's score of 0.71 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.
NewAmsterdam Pharma currently has a consensus target price of $41.60, indicating a potential upside of 124.02%. Eton Pharmaceuticals has a consensus target price of $24.00, indicating a potential upside of 65.60%. Given NewAmsterdam Pharma's higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Eton Pharmaceuticals.
Eton Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma.
Summary
NewAmsterdam Pharma beats Eton Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ETON) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ETON Stock Alerts